Targets › LCK
2 programs from 2 companies in 16 trials: 7 Phase 1, 6 Phase 2, 3 Phase 3; Oncology; next expected readout Dec 2026.
Non-receptor tyrosine-protein kinase that plays an essential role in the selection and maturation of developing T-cells in the thymus and in the function of mature T-cells. Plays a key role in T-cell antigen receptor (TCR)-linked signal transduction pathways. (UniProt, P06239)
Open in Phaseline: the race on LCK, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Xynomic Pharmaceuticals | Pazopanib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase LCK inhibitor | CSF1R, KIT, LCK, FGFR3, FGFR1 | Phase 3 | Renal Cell Carcinoma; Leiomyosarcoma or Carcinosarcoma; Soft Tissue Sarcoma; Rhabdomyosarcoma, Recurrent, Refractory … | Dec 2026 |
| National Cancer Institute (NCI) | Pazopanib Hydrochloride Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase LCK inhibitor | CSF1R, KIT, LCK, FGFR3, FGFR1 | Phase 3 | Clear Cell Renal Cell Carcinoma; Foregut Neuroendocrine Tumor; Solid Neoplasm | Feb 2027 |
Renal Cell Carcinoma (2) Leiomyosarcoma or Carcinosarcoma (2) Clear Cell Renal Cell Carcinoma (1) Foregut Neuroendocrine Tumor (1) Solid Neoplasm (1) Soft Tissue Sarcoma (1) Rhabdomyosarcoma, Recurrent, Refractory (1) Kidney Cancer (1) Solid Tumor, Adult (1) Advanced Soft-tissue Sarcoma (1) Glioblastoma Multiforme (1) Refractory or Recurrent Solid Tumor (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.